These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38369231)

  • 21. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypically Diverse Dominant Maculopathy.
    Sinha D; Steyer B; Shahi PK; Mueller KP; Valiauga R; Edwards KL; Bacig C; Steltzer SS; Srinivasan S; Abdeen A; Cory E; Periyasamy V; Siahpirani AF; Stone EM; Tucker BA; Roy S; Pattnaik BR; Saha K; Gamm DM
    Am J Hum Genet; 2020 Aug; 107(2):278-292. PubMed ID: 32707085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA therapeutics for retinal diseases.
    Gemayel MC; Bhatwadekar AD; Ciulla T
    Expert Opin Biol Ther; 2021 May; 21(5):603-613. PubMed ID: 33307874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.
    Quemener AM; Centomo ML; Sax SL; Panella R
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.
    Carroll JB; Warby SC; Southwell AL; Doty CN; Greenlee S; Skotte N; Hung G; Bennett CF; Freier SM; Hayden MR
    Mol Ther; 2011 Dec; 19(12):2178-85. PubMed ID: 21971427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gapmer Antisense Oligonucleotides to Selectively Suppress the Mutant Allele in COL6A Genes in Dominant Ullrich Congenital Muscular Dystrophy.
    Aguti S; Marrosu E; Muntoni F; Zhou H
    Methods Mol Biol; 2020; 2176():221-230. PubMed ID: 32865794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-cell map of antisense oligonucleotide activity in the brain.
    Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
    Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing.
    Aguti S; Cheng S; Ala P; Briggs S; Muntoni F; Zhou H
    Mol Ther Nucleic Acids; 2024 Sep; 35(3):102237. PubMed ID: 38993932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides.
    Reidenbach AG; Minikel EV; Zhao HT; Guzman SG; Leed AJ; Mesleh MF; Kordasiewicz HB; Schreiber SL; Vallabh SM
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31861275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.
    Helm J; Schöls L; Hauser S
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bestrophin 1 and retinal disease.
    Johnson AA; Guziewicz KE; Lee CJ; Kalathur RC; Pulido JS; Marmorstein LY; Marmorstein AD
    Prog Retin Eye Res; 2017 May; 58():45-69. PubMed ID: 28153808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inherited Retinal Diseases and Retinal Organoids as Preclinical Cell Models for Inherited Retinal Disease Research.
    Ashworth KE; Weisbrod J; Ballios BG
    Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease.
    Moore SM; Skowronska-Krawczyk D; Chao DL
    Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
    Gerard X; Garanto A; Rozet JM; Collin RW
    Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
    Rigo F; Seth PP; Bennett CF
    Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat.
    Li L; Shen X; Liu Z; Norrbom M; Prakash TP; O'Reilly D; Sharma VK; Damha MJ; Watts JK; Rigo F; Corey DR
    Nucleic Acid Ther; 2018 Feb; 28(1):23-33. PubMed ID: 29341839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutant Best1 Expression and Impaired Phagocytosis in an iPSC Model of Autosomal Recessive Bestrophinopathy.
    Marmorstein AD; Johnson AA; Bachman LA; Andrews-Pfannkoch C; Knudsen T; Gilles BJ; Hill M; Gandhi JK; Marmorstein LY; Pulido JS
    Sci Rep; 2018 Mar; 8(1):4487. PubMed ID: 29540715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity.
    Liang XH; Nichols JG; De Hoyos CL; Crooke ST
    Nucleic Acids Res; 2020 Sep; 48(17):9840-9858. PubMed ID: 32870273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.